Effects of dendritic cells transfected with full-length wild-type p53 and stimulated by gastric cancer lysates on immune response

被引:0
|
作者
Hua-Wen Sun Qi-Bing Tang Yong-Jun Cheng Sheng-Qian Zou Department of General Surgery
机构
关键词
Effects of dendritic cells transfected with full-length wild-type p53 and stimulated by gastric cancer lysates on immune response; MHC; type; length;
D O I
暂无
中图分类号
R735.2 [胃肿瘤];
学科分类号
100214 ;
摘要
AIM:To investigate the effects of dendritic cells(DCs)transfected with full-length wild-type p53 and stimulatedby gastric cancer lysates on immune response.METHODS:The wild-type p53was transduced to DCs withadenovirus,and the DCs were stimulated by gastric cancerlysates.The surface molecules(B7-1,B7-2,MHC-Ⅰ,MHC-Ⅱ)of all DCs were detected by FACS,and the ability of the DCsto induce efficient and specific immunological response inanti-51Cr-labeled target cells was studied.BALB/c miceinjected with DCs and Mk28 were established,and CTLresponse in mice immunized with Lywt-p53DC was evaluated.Tumor-bearing mice were treated with Lywt-p53DC.RESULTS:The surface molecules of Lywt-p53DC had a highexpression of B7-1(86.70±0.07%),B7-2(18.77±0.08%),MHC-Ⅰ(87.20±0.05%)and MHC-Ⅱ(56.70±0.07%);Tlymphocytes had a specific CTL lysis ability induced by Lywt-p53DC;the CTL lysis rate was as high as 81%.The immuneprotection of Lywtp-53DC was obvious,the tumor diameterin Lywtp-53DC group was 3.10±0.31 mm,2.73±0.23mm,3.70±0.07 mm on d 13,16 and 19,respectively,whichwere smaller than control,DC,wtp53DC and LyDC group(P<0.05).Tumor growth rate in Lywtp53DC group wasslower than that in other groups(P<0.05).CONCLUSION:DCs transfected with wild-type p53 andstimulated by gastric cancer lysates have specific CTL killingactivity.
引用
收藏
页码:2595 / 2597
页数:3
相关论文
共 50 条
  • [21] Wild-Type p53 Regulates Apoptosis of Human Breast Cancer Cells
    Zhang, Xuliang
    Yu, Guozheng
    Cai, Lei
    Jian, Ming
    Cai, Lixia
    Xu, Dong
    DISCOVERY MEDICINE, 2024, 36 (191) : 2445 - 2453
  • [22] Wild-type p53 in cancer cells: When a guardian turns into a blackguard
    Kim, Ella
    Giese, Alf
    Deppert, Wolfgang
    BIOCHEMICAL PHARMACOLOGY, 2009, 77 (01) : 11 - 20
  • [23] Failure of wild-type p53 gene therapy in human cancer cells expressing a mutant p53 protein
    A Vinyals
    M A Peinado
    M Gonzalez-Garrigues
    M Monzó
    R D Bonfil
    A Fabra
    Gene Therapy, 1999, 6 : 22 - 33
  • [24] Therapeutic potential of recombinant p53 overexpression in breast cancer cells expressing endogenous wild-type p53
    Li, PX
    Bui, T
    Gray, D
    Klamut, HJ
    BREAST CANCER RESEARCH AND TREATMENT, 1998, 48 (03) : 273 - 286
  • [25] Induction of wild-type p53 activity in human cancer cells by ribozymes that repair mutant p53 transcripts
    Watanabe, T
    Sullenger, BA
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (15) : 8490 - 8494
  • [26] Failure of wild-type p53 gene therapy in human cancer cells expressing a mutant p53 protein
    Vinyals, A
    Peinado, MA
    Gonzalez-Garrigues, M
    Monzó, M
    Bonfil, RD
    Fabra, A
    GENE THERAPY, 1999, 6 (01) : 22 - 33
  • [27] The Inhibition of Autophagy Sensitises Colon Cancer Cells with Wild-Type p53 but Not Mutant p53 to Topotecan Treatment
    Li, Dan-Dan
    Sun, Ting
    Wu, Xiao-Qi
    Chen, Shu-Peng
    Deng, Rong
    Jiang, Shan
    Feng, Gong-Kan
    Pan, Jing-Xuan
    Zhang, Xiao-Shi
    Zeng, Yi-Xin
    Zhu, Xiao-Feng
    PLOS ONE, 2012, 7 (09):
  • [28] Therapeutic potential of recombinant p53 overexpression in breast cancer cells expressing endogenous wild-type p53
    Peixiang Li
    Thuy Bui
    Dawn Gray
    Henry J. Klamut
    Breast Cancer Research and Treatment, 1998, 48 : 273 - 286
  • [29] An accelerated senescence response to radiation in wild-type p53 glioblastoma multiforme cells
    Quick, Quincy A.
    Gewirtz, David A.
    JOURNAL OF NEUROSURGERY, 2006, 105 (01) : 111 - 118
  • [30] Effects of adenoviral wild-type p53 gene transfer in p53-mutated lymphoma cells
    Buttgereit, P
    Schakowski, F
    Märten, A
    Brand, K
    Renoth, S
    Ziske, C
    Schöttker, B
    Ebert, O
    Schroers, R
    Schmidt-Wolf, IGH
    CANCER GENE THERAPY, 2001, 8 (06) : 430 - 439